GPGloria S. Pryhuber

Gloria S. Pryhuber

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Gloria S. Pryhuber has a total of 843 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    602.2 Donor Acceptance Criteria for URMC HTC SenNet Inclusion v2

    by Gloria S Pryhuber

    Purpose and Scope of the Procedure Standardize process for receiving tissue or organ donations for research Scope: Coordination of screening, acceptance and receipt of tissue for research programs Principles Organ donations rejected for transplantation can be used to understand human tissue cellularity, structure, disease, and development, ultimately to improve care of patients with disease Rapid, standardized and safe processing of human tissue for the HTC requires coordination of a team of staff, materials and attention to protocols Rapid processing is required to maintain the tissues in a state as close to native (as from originating living body) as possible Ultra-high resolution CT Scan in an inflated state will provide a high-level comparative assessment of human lung structure across developmental ages (See Protocol 603). CT scans of other organs, by the HTC, will be considered.

  • Open Access

    640.1_URMC_HTC_Heart and Non-Lung Tissue Processing v1

    by Gloria Pryhuber, Heidie Huyck, Ariana Pitonzo

    Purpose and Scope of the Procedure Standardize process for processing tissue and organ donations into components for storage and research use. Scope: coordination of receipt, gross dissection and preservation of tissue

  • Consensus Lung Cell Reference: The Collaborative Cross-Consortium and Country Lung Cell Nomenclature Project (C3LCN). An Official American Thoracic Society Workshop Report

    by Gloria S Pryhuber, Martijn Nawijn, Denise Al Alam, Bruce Aronow, Martin Banchero, Nicholas Banovich, Pascal Barbry, Maria Basil, Kevin Burns, Janette Burgess, et al.

    Rapid advances in single-cell technologies now allow measurement of thousands of transcripts and other molecular features of individual cells offering unprecedented insight into lung biology in homeostasis and in disease. The accelerated generation of multimodal data has, however, been accompanied by the reporting of putatively “novel” cell types described without consensus regarding their ontogeny, identity, function, or defining markers. To fully realize the value of the technological advances and to enable rigorous comparison across studies, respiratory research will benefit from standardized, quantitative, and biologically grounded cell classifications and nomenclature. Achieving the transformative potential of the multimodal data will depend on common, machine- and human-readable nomenclature, structured and expandable dictionary and atlas resources, and clear methodological standards that ensure consistency as technologies evolve. The American Thoracic Society (ATS) recognized the importance of promoting a common nomenclature to enhance equitable access and utility of the vast amounts of multimodal data generated by the lung research community. The Collaborative Cross-Consortium and Country Lung Cell Nomenclature Project (C3LCN) was adopted as an ATS Assembly Project in 2024. This is the consensus report outlining the goals and framework of the Project to foster coordinated progressive lung cell research to include: 1) providing best practices for analysis, publication and reporting of lung single-cell transcriptomic datasets; 2) establishing a contemporary lexicon for healthy adult human cells of the lower respiratory tract with structured, persistent, and resolvable identifiers; 3) defining a scalable taxonomy to organize a common lung cell nomenclature; 4) offering tools to support collaboration, knowledge dissemination, and translational advances rooted in modern lung biology augmenting, not replacing, pre-genomic biological knowledge; and 5) describing an infrastructure capable of incorporating new ontological refinements as higher-resolution, multimodal single-cell and spatial datasets emerge, cellular heterogeneity is better defined, and disease-associated abnormal cell types and reactive cell states are increasingly recognized and mechanistically interrogated. Together, this coordinated effort aims to provide the foundation necessary for a robust, harmonized, and expandable nomenclature for lung science.


  • Targeted Biospecimen Collection to Meet High Priority Pediatric Health Needs: The Developmental Genotype-Tissue Expression Project

    by Patrick M. Van Hoose, Rebecca L. Linn, Melissa W. VonDran, Deanne Taylor, Thomas G. Blanchard, Raquel G. Hernandez, Melissa A. Faith, Gloria S. Pryhuber, Heidie L. Huyck, Alexandra N. LeFevre, et al.

    Introduction: The gene expression patterns that drive human development are not fully understood. Objectives: To address this major public health need for pediatric clinicians, scientists, parents, and children, the National Institute of Health established the Developmental Genotype-Tissue Expression (dGTEx) project to study tissue-specific gene expression during the normal pediatric development of human organs, tissues, and cells. Methods: Obtaining suitable, well-annotated pediatric biospecimens for innovative molecular methodologies and rigorous data analysis is both a high priority and unmet health need for the pediatric research community. Results: Here, we report on the advancements and challenges in dGTEx with pediatric-specific tissue collection methodologies, metadata collection, and tissue verification processes. Conclusion: Collectively, the procedures, data, and biospecimens from dGTEx will provide an unparalleled resource for pediatric clinicians and scientists. The aim of establishing this resource is to gain a better understanding of pediatric gene expression and regulation across all body systems and stages of development, with potentially deeper insights into, and the development of new treatment options for, both diseases of childhood and later-onset, developmental-linked diseases in adults.

  • An update to the classification, evaluation, and management of childhood interstitial lung disease in infancy: an official American Thoracic Society Clinical Practice Guideline

    by Matthew D McGraw, Emily DeBoer, Jason P Weinman, Gail H Deutsch, Jennifer Pogoriler, Maureen B Parenti, Geoffrey Kurland, Joshua Blatter, Alicia M Casey, Robin R Deterding, et al.

    Background: Childhood interstitial lung diseases (chILD) are a heterogeneous group of rare disorders. In 2013, the American Thoracic Society (ATS) developed a guideline regarding the classification, evaluation, and management of children <2 years old with chILD. The current guideline provides updated recommendations regarding genetic testing, chest imaging, lung biopsy, and lung transplant referral. Methods: The Grading of Recommendations, Assessment, Development, and Evaluation approach was used to form clinical questions, summarize evidence, and develop recommendations, following ATS policies and procedures. A multidisciplinary panel with expertise in chILD formulated recommendations addressing diagnostic tools and referral for lung transplant evaluation. Results: Rapid and broad genetic testing is recommended for infants with chILD and respiratory failure (strong recommendation). Chest computed tomography (CT) remains an important part of the diagnostic evaluation (conditional recommendation). Surgical lung biopsy is recommended when there is urgency to identify a specific chILD disorder and genetic testing is not feasible, timely, or inconclusive; to identify histopathologic “treatable traits”; or to inform prognosis (strong recommendation). Referral for lung transplant evaluation is recommended for children with specific chILD disorders with predictable poor outcomes (strong recommendation). Repeat chest CT to aid decision-making, prognosis, and/or change therapies is suggested for children with chILD diagnosed before age 2 years (conditional recommendation). Conclusions: This guideline provides evidence-based recommendations for genetic testing, chest imaging, lung biopsy, and referral for lung transplant evaluation to improve the diagnostic evaluation and management of children <2 years with chILD. Implementing this guideline will hopefully increase genetic testing for chILD, inform the diagnostic evaluation and disease monitoring of chILD, and identify future research priorities for chILD.


  • Open Access

    Reproducible-by-design: Romics Processor, a FAIR ecosystem for multi-omics and spatial-omics analysis

    by Brittney L. Gorman, Harsh Bhotika, Matthew Jehrio, Jeffrey M. Purkerson, Frederic Carlin, Ernesto Nakayasu, Andrew M. Dylag, Ravi S. Misra, Joshua Adkins, Christopher R. Anderton, et al.

    Multi-omics and spatial-omics technologies are exploding in use, producing increasingly complex datasets. Existing bioinformatics tools are developing rapidly but fail to fully enforce the FAIR principles, leaving the field vulnerable to escalating issues in computational reproducibility. Here, we introduce a reproducible-by-design paradigm represented in an omics data processing package, RomicsProcessor. At its core, the “Romics_object”, which is a self-contained digital artifact that encapsulates the full history of the data from the original data to the fully processed state, capturing the details of the transformative steps and the required dependencies. This architecture ensures that computational workflows are fully portable and reproducible. In this manuscript, we demonstrate RomicProcessor’s computational capabilities and scalability on diverse datasets, including bulk proteomics, large-scale multiplexed immunofluorescence, and multi-batch mass spectrometry imaging. Providing a robust framework for truly FAIR Data Principles-based analysis, RomicsProcessor is a blueprint for the next generation of reproducible bioinformatics tools that can dramatically accelerate discovery in multi-omics biology in the era of artificial intelligence.


  • Open Access

    Multiscale metabolic mapping of lung tissue via coregistered mass spectrometry and nonlinear optical imaging

    by Brittney L. Gorman, Zhi Li, Gail Deutsch, Heidie L. Huyck, Niana Beishembieva, Harsh Bhotika, Heather Olson, Jorge Villazon, Ping Yu, Gloria S. Pryhuber, et al.

    The lung is a highly heterogeneous organ that is composed of numerous microanatomical units, each essential for maintaining intricate functions that work in concert. Disruptions in the molecular and cellular mechanisms can cause tissue fibrosis, inflammation, and severe breathing difficulties, which are common characteristics of the disease of prematurity, bronchopulmonary dysplasia (BPD). BPD’s molecular changes are not well understood, and this has hindered effective diagnosis and treatment. Here, we present a multimodal imaging workflow for detailed molecular and metabolic characterization of lung tissue at multiple spatial scales. We also developed a hierarchical multimodal registration network for precise coregistration of the data from each modality. Our results show that this approach can reveal previously unknown metabolic changes in distinct functional tissue units affected by disease, including altered lipid distributions, reduced optical redox states, and collagen remodeling. This multimodal approach provided detailed maps of molecular shifts occurring in distinct microanatomical features that, when adopted to interrogate this and other tissue types, has the potential to enable the discovery of new therapeutics.


  • Open Access

    703 and 704. Whole Blood Peripheral Blood Mononuclear Cell (PBMC) Isolation, Freezing and Thawing. LungMAP HTC SOP v1

    by Ravi Misra, Gautam Bandyopadhyay, Heidie Huyck, Sally Quataert, Gloria Pryhuber

    Purpose and Scope of the Procedure or Laboratory Assay Scope: To outline the retrieval of peripheral blood mononuclear cells (PBMC), from whole blood collected in anticoagulant, using Ficoll-Hypaque density gradient centrifugation. This protocol was used to isolate PBMC for samples received for LungMAP HTC and HuBMAP MOSDAP Project. Scientific Principles: Human Peripheral Blood Mononuclear cells (PBMCs) and platelets have a lower density than Ficoll-Hypaque (1.077 g/L) and are separated from higher density granulocytes and red blood cells when centrifuged after either under or overlaying the diluted blood on the Ficoll-Hypaque layer. Blood from young infants may contain immature red blood cells that may contaminate the upper buffy coat layer after centrifugation. The contaminating RBC may be removed from the infant buffy coat by a second Ficoll-Hypaque centrifugation step. However, since premature infant blood volumes are so small, optimizing the yield of PBMCs/ml of collected blood is critical. So a second ficoll step is not recommended. An RBC lysis step and an anti-RBC surface marker (CD252) will be used to remove and identify in flow cytometry those RBC not removed from the cell sample. To retain cellular integrity, we recommend that cells be frozen at a slow controlled rate of minus one degree Celsius per minute in cryoprotectant medium containing 10% dimethylsulfoxide (DMSO). Use of 90% FBS improves post-thaw viability in our experience. The DMSO acts to prevent ice crystal formation during the slow freezing process, maintaining cell viability. Some cell types such as PBMC may be stored short term (less than one week) at -800C or long term in a liquid nitrogen freezer. For maximum recovery and viability upon thawing, cells should be healthy prior to freezing. Successful cell recovery from the frozen state requires rapid but gentle thawing of the cells followed by immediate dilution and removal of cryoprotectant medium from the cells. Note the protocol suggesting thawing only 1-2 vials at a time and initial slow, 1-2 drop, addition of buffer to avoid shocking the cells.

  • Open Access

    URMC TriState SenNet TMC Visium HD Spatial Transcriptomics of Human Lung Tissue v1

    by Sadiya Shaikh, Gloria Pryhuber, Irfan Rahman

    This protocol describes the preparation, processing, imaging, library construction, sequencing, and downstream analysis of human pediatric lung tissue specimens using the 10x Genomics Visium HD Spatial Gene Expression platform. The workflow was applied to lung tissues obtained from pediatric control donors and donors with bronchopulmonary dysplasia (BPD) to generate high-resolution spatial maps of gene expression within the developing and diseased lung. The protocol preserves tissue architecture while enabling spatially resolved transcriptomic profiling of cellular and molecular heterogeneity associated with normal lung development and BPD pathology. Spatial transcriptomic datasets generated using this workflow was integrated with complementary single-nucleus RNA sequencing, multiplex fluorescence imaging, and spatial proteomics datasets to support construction of a comprehensive pediatric lung atlas, contributing to the Cellular Senescence Network (SenNet) efforts to map tissue microenvironments and cellular states across health and disease.

  • Open Access

    SenSet defines cell-type specific senescence signatures in the aged human lung

    by Euxhen Hasanaj, Delphine Beaulieu, Cankun Wang, Qianjiang Hu, Lorena Rosas, Marta Bueno, John C Sembrat, Ricardo H Pineda, Maria Camila Melo-Narvaez, Nayra Cardenes, et al.

    Cellular senescence is defined as an irreversible growth arrest observed when cells are exposed to a variety of stressors, including DNA damage, oxidative stress, or nutrient deprivation. Although senescence is a well-established driver of aging and age-related diseases, it is a highly heterogeneous process with significant variations across organisms, tissues, and cell types. The relatively low abundance of senescent cells in healthy aged tissues poses a major challenge to the longitudinal study of senescence in specific organs, including the human lung. To overcome this limitation, we developed a positive-unlabeled learning framework to generate a comprehensive list of senescence marker genes in human lungs (termed SenSet) using the largest publicly available single-cell lung dataset, the Human Lung Cell Atlas (HLCA). We validated SenSet in a highly complex ex vivo human 3D lung tissue culture model subjected to the senescence inducers bleomycin, doxorubicin, or irradiation, and established its sensitivity and accuracy in characterizing senescence. Using SenSet, we identified and validated cell-type-specific senescence signatures in distinct lung cell populations upon aging and environmental exposure. Our study provides a comprehensive analysis of senescent cells in the healthy aging lung, presenting fundamental implications for our understanding of major lung diseases, including cancer, fibrosis, chronic obstructive pulmonary disease, or asthma.